Can functional autoantibodies against the endothelin A receptor alter signaling and promote vascular effects?

Functional autoantibodies directed at the endothelin A receptor (ETAR) are most often studied in systemic sclerosis and scleroderma renal crisis. The available evidence supports agonist-like alteration of ETAR-associated signaling and experimental vascular hyperreactivity; endothelial dysfunction in the clinical sense remains less directly established.

Clinical and experimental vascular evidence

• Patient-derived IgG containing anti-ETAR activity increased vasoconstriction and amplified responses to endothelin-1 and angiotensin II in isolated pulmonary and renal artery preparations. These effects were reduced by ETAR/AT1R antagonism, consistent with ETAR-related signaling and AT1R–ETAR crosstalk.
• Thus, the evidence supports a capacity to promote vasoconstrictive vascular effects in experimental systems, but does not establish that anti-ETAR antibodies independently cause hypertension, ischemia, or impaired perfusion in an individual patient.

Endothelial and molecular mechanisms

• Anti-ETAR-positive systemic-sclerosis IgG induced ERK1/2 phosphorylation, calcium signaling, and increased TGF-β expression in human microvascular endothelial cells; receptor antagonists inhibited several responses.
• Endothelial inflammatory activation was also observed: IgG containing anti-ETAR/anti-AT1R increased IL-8 and VCAM-1, while the ETAR antagonist sitaxentan reduced IL-8.
• These findings provide a credible mechanistic pathway from antibody-associated receptor stimulation to endothelial activation, inflammatory adhesion signaling, and calcium-dependent vascular contraction.

Interpretation

• A key limitation is specificity: patient IgG commonly contains anti-AT1R antibodies and other immunoglobulins. Antagonist sensitivity supports ETAR participation but does not fully prove that purified anti-ETAR antibodies alone produce each effect. One recent purified-IgG study did not detect AT1R- or ETAR-dependent endothelial activation in its assays.

Bottom line

• Functional anti-ETAR autoantibody-containing IgG can alter ETAR-associated signaling and can enhance experimental vasoconstrictive responses. Endothelial dysfunction is biologically plausible through calcium, ERK1/2, TGF-β, IL-8, and VCAM-1 pathways, but direct evidence of antibody-specific impairment of validated endothelial function in humans is limited.